A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer
Hyun Jung Lee, Dae-Seog Heo, Joo-Youn Cho, Sae-Won Han, Hye-Jung Chang, Hyeon-Gyu Yi, Tae-Eun Kim, Se-Hoon Lee, Do-Youn Oh, Seock-Ah Im, In-Jin Jang, Yung-Jue Bang
Cancer Res Treat. 2014;46(3):234-242.   Published online 2014 Jul 15     DOI: https://doi.org/10.4143/crt.2014.46.3.234
Citations to this article as recorded by Crossref logo
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance
Hai Wang, Yutong Liang, Yue Yin, Jie Zhang, Wen Su, Alisa M. White, Bin Jiang, Jiangsheng Xu, Yuntian Zhang, Samantha Stewart, Xiongbin Lu, Xiaoming He
Nature Communications.2021;[Epub]     CrossRef
The intravenous to oral switch of taxanes: strategies and current clinical developments
Marit AC Vermunt, Andries M Bergman, Eric van der Putten, Jos H Beijnen
Future Oncology.2021; 17(11): 1379.     CrossRef
Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice
Mahdi Ghadi, Seyed Jalal Hosseinimehr, Fereshteh Talebpour Amiri, Alireza Mardanshahi, Zohreh Noaparast
European Journal of Pharmacology.2021; : 173892.     CrossRef
Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
Michael P. Smolinski, Sameer Urgaonkar, Laura Pitzonka, Murray Cutler, GwanSun Lee, Kwee Hyun Suh, Johnson Y. N. Lau
Journal of Medicinal Chemistry.2021; 64(7): 3677.     CrossRef
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study
Christopher G. C. A. Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Blair McLaren, Noelyn Anne Hung, Katriona Clarke, Tsu‐Yi Chao, Ming‐Shen Dai, Hsien‐Tang Yeh, David L. Cutler, Douglas Kramer, Jimmy He, Jay Zhi, Wing‐Kai Chan, Rudolf Kwan, S
British Journal of Clinical Pharmacology.2021;[Epub]     CrossRef
Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin
Yuanfeng Wei, Shengyan Zhou, Tianyun Hao, Jianjun Zhang, Yuan Gao, Shuai Qian
European Journal of Pharmaceutical Sciences.2019; 129: 21.     CrossRef
DHP23002 as a next generation oral paclitaxel formulation for pancreatic cancer therapy
Eunseo Jang, Minhee Son, Junhee Jang, In-Hyun Lee, Sol Kim, Taejun Kwon, Yong-hyun Jeon, Woo-Suk Koh, Kil-Soo Kim, Sang Kyoon Kim, Sumitra Deb
PLOS ONE.2019; 14(11): e0225095.     CrossRef
Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles
Marco C. Cavaco, Carolina Pereira, Bruna Kreutzer, Luis F. Gouveia, Beatriz Silva-Lima, Alexandra M. Brito, Mafalda Videira
European Journal of Pharmaceutics and Biopharmaceutics.2017; 110: 76.     CrossRef
Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor
Jin Cheul Kim, Kyeong Soo Kim, Dong Shik Kim, Sung Giu Jin, Dong Wuk Kim, Yong Il Kim, Jae-Hyun Park, Jong Oh Kim, Chul Soon Yong, Yu Seok Youn, Jong Soo Woo, Han-Gon Choi
International Journal of Pharmaceutics.2016; 506(1-2): 93.     CrossRef
Direct in vivo evidence on the mechanism by which nanoparticles facilitate the absorption of a water insoluble, P-gp substrate
Ramesh Soundararajan, Kenji Sasaki, Lisa Godfrey, Uchechukwu Odunze, Nancy Fereira, Andreas Schätzlein, Ijeoma Uchegbu
International Journal of Pharmaceutics.2016; 514(1): 121.     CrossRef